Why MoonLake’s $200 Million Funding Could Be a Turning Point for Hidradenitis Suppurativa Patients

Zug, Wednesday, 24 June 2026.
MoonLake Immunotherapeutics secured $200 million in a public offering, a vote of confidence in its lead drug, sonelokimab, for hidradenitis suppurativa (HS). This rare, painful skin disease affects millions, yet only 3% receive advanced treatments. Sonelokimab’s Phase 3 trials delivered groundbreaking results: 67% of patients achieved a 75% reduction in symptoms at one year, with 33% reaching complete clearance. Adolescents responded even faster, with 70% hitting key efficacy milestones. The funding fuels a planned FDA submission by September 2026, positioning sonelokimab as a potential best-in-class therapy. If approved, it could redefine HS treatment, offering hope for a condition where current options fall short.